This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
World Health Organization. Elimination of mother-to-child transmission (EMTCT) of HIV and syphilis: Global guidance on criteria and processes for validation, June 2014. Available at http://www.who.int/reproductivehealth/publications/rtis/9789241505888/en/. Accessed April 7, 2017.World Health OrganizationElimination of mother-to-child transmission (EMTCT) of HIV and syphilis: Global guidance on criteria and processes for validationJune 2014. Available athttp://www.who.int/reproductivehealth/publications/rtis/9789241505888/en/Accessed April 72017Search in Google Scholar
Lolekha R, Boonsuk S, Plipat T, Martin M, Tonputsa C, Punsuwan N, et al. Elimination of mother-to-child transmission of HIV – Thailand. MMWR Morbidity and mortality weekly report. 2016; 65:562-6.LolekhaRBoonsukSPlipatTMartinMTonputsaCPunsuwanNElimination of mother-to-child transmission of HIV – ThailandMMWR Morbidity and mortality weekly report.201665562610.15585/mmwr.mm6522a227281244Search in Google Scholar
Plipat T, Naiwatanakul T, Rattanasuporn N, Sangwanloy O, Amornwichet P, Teeraratkul A, et al. Reduction in mother-to-child transmission of HIV in Thailand, 2001–2003: Results from population-based surveillance in six provinces. Aids. 2007; 21:145-51.PlipatTNaiwatanakulTRattanasupornNSangwanloyOAmornwichetPTeeraratkulAReduction in mother-to-child transmission of HIV in Thailand, 2001–2003: Results from population-based surveillance in six provincesAids.2007211455110.1097/QAD.0b013e328010e02d17197804Search in Google Scholar
Phanuphak N, Lolekha R, Chokephaibulkit K, Voramongkol N, Boonsuk S, Limtrakul A, et al. Practice guideline: Thai national guidelines for the prevention of mother-to-child transmission of HIV: March 2010. Asian Biomed (Res Rev News). 2010; 4:529-40.PhanuphakNLolekhaRChokephaibulkitKVoramongkolNBoonsukSLimtrakulAPractice guideline: Thai national guidelines for the prevention of mother-to-child transmission of HIV: March 2010Asian Biomed (Res Rev News).201045294010.2478/abm-2010-0067Search in Google Scholar
Ongwandee S, Lertpiriyasunondh C, Lolekha R, Sukkul A, editors. National guidelines on HIV/AIDS diagnosis and treatment: Thailand 2014. Bangkok: The Agricultural Co-operative Federation of Thailand; 2014.OngwandeeSLertpiriyasunondhCLolekhaRSukkulANational guidelines on HIV/AIDS diagnosis and treatment: Thailand 2014BangkokThe Agricultural Co-operative Federation of Thailand2014Search in Google Scholar
National AIDS Prevention and Alleviation Committee. UNGASS Country Progress Report: Thailand January 2008-December 2009. Available at http://www.aidsdatahub.org/sites/default/files/documents/thailand_2010_country_progress_report_en.pdf. Accessed Feb 15, 2017.National AIDS Prevention and Alleviation CommitteeUNGASS Country Progress Report: Thailand January 2008-December 2009. Available athttp://www.aidsdatahub.org/sites/default/files/documents/thailand_2010_country_progress_report_en.pdfAccessedFeb 152017Search in Google Scholar
Thai national AIDS Committee. 2014 Thailand AIDS response progress report (reporting period: 2012-2013). Available at http://www.aidsdatahub.org/sites/default/files/publication/Thailand_narrative_report_2014.pdf.Accessed January 15, 2017.Thai national AIDS Committee2014Thailand AIDS response progress report (reporting period: 2012-2013)Available athttp://www.aidsdatahub.org/sites/default/files/publication/Thailand_narrative_report_2014.pdfAccessedJanuary 152017Search in Google Scholar
Tonpudsa C, Lolekha R, Pavaputanondh P, Puthanakit T, Kosalaraksa P, Petdachai W, et al. Remaining causes of Mother-to-Child HIV Transmission (MTCT) in Thailand: barriers for achieving <1% of MTCT rate. 9th IAS Conference on HIV Science July 23–26, 2017. Paris, France. Poster abstract No. A-854-0250-02238.TonpudsaCLolekhaRPavaputanondhPPuthanakitTKosalaraksaPPetdachaiWRemaining causes of Mother-to-Child HIV Transmission (MTCT) in Thailand: barriers for achieving <1% of MTCT rate9th IAS Conference on HIV Science July 23–262017Paris, FrancePoster abstract No. A-854-0250-02238Search in Google Scholar
Sumet Ongwandee, Sasisopin Kiertiburanakul, Anchalee Avihingsanon, Ake-Chittra Sukkul, Rangsima Lolekha, editors. Thailand National Guidelines on HIV/AIDS Treatment and Prevention 2017. Bangkok: The Agricultural Co-operative Federation of Thailand; 2017. Available at http://www.thaiaidssociety.org/index.php?option=com_content&view=article&id=79&Itemid=86. Accessed March 12, 2017.SumetOngwandeeSasisopinKiertiburanakulAnchaleeAvihingsanonAke-ChittraSukkulRangsimaLolekhaThailand National Guidelines on HIV/AIDS Treatment and Prevention 2017BangkokThe Agricultural Co-operative Federation of Thailand; 2017Available athttp://www.thaiaidssociety.org/index.php?option=com_content&view=article&id=79&Itemid=86AccessedMarch 122017Search in Google Scholar
Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States 2016. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf. Accessed January 20, 2017.Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal TransmissionRecommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States 2016Available athttp://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdfAccessed January 202017Search in Google Scholar
de Ruiter A, Taylor GP, Clayden P, Dhar J, Gandhi K, Gilleece Y, et al. British HIV association guidelines for the management of HIV infection in pregnant women 2012 (2014 interim review). HIV Med. 2014; 15: 1-77.de RuiterATaylorGPClaydenPDharJGandhiKGilleeceYBritish HIV association guidelines for the management of HIV infection in pregnant women 2012 (2014 interim review)HIV Med.20141517710.1111/hiv.1218525604045Search in Google Scholar
World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendation for a public health approach. Geneva: World Health Organization; 2013. Available at http://www.who.int/hiv/pub/guidelines/arv2013/en/. Accessed December 31, 2014.World Health OrganizationConsolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendation for a public health approachGeneva: World Health Organization2013Available athttp://www.who.int/hiv/pub/guidelines/arv2013/en/AccessedDecember 312014Search in Google Scholar
World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach. 2nd ed. Geneva: World Health Organization. Available at http://www.who.int/hiv/pub/arv/arv-2016/en/. Accessed January 20, 2017.World Health OrganizationConsolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infectionRecommendations for a public health approach2ndGenevaWorld Health OrganizationAvailable athttp://www.who.int/hiv/pub/arv/arv-2016/en/AccessedJanuary 202017Search in Google Scholar
World Health Organization. Guidance on couples HIV testing and counselling including antiretroviral therapy for treatment and prevention in serodiscordant couples: recommendations for a public health approach. Geneva: World Health Organization; 2012.World Health OrganizationGuidance on couples HIV testing and counselling including antiretroviral therapy for treatment and prevention in serodiscordant couples: recommendations for a public health approachGenevaWorld Health Organization2012Search in Google Scholar
Lolekha R, Kullerk N, Wolfe MI, Klumthanom K, Singhagowin T, Pattanasin S, et al. Assessment of a couples HIV counseling and testing program for pregnant women and their partners in antenatal care (ANC) in 7 provinces, Thailand. BMC Int Health Hum Rights. 2014; 14:39. 10.1186/s12914-014-0039-2.LolekhaRKullerkNWolfeMIKlumthanomKSinghagowinTPattanasinSAssessment of a couples HIV counseling and testing program for pregnant women and their partners in antenatal care (ANC) in 7 provinces, ThailandBMC Int Health Hum Rights.2014143910.1186/s12914-014-0039-2430182925539670Open DOISearch in Google Scholar
Asavapiriyanont S, Lolekha R, Roongpisuthipong A, Wiratchai A, Kaoiean S, Suksripanich O, et al. Sexually transmitted infections among HIV-infected women in Thailand. BMC Public Health. 2013; 13:373. 10.1186/1471-2458-13-373.AsavapiriyanontSLolekhaRRoongpisuthipongAWiratchaiAKaoieanSSuksripanichOSexually transmitted infections among HIV-infected women in ThailandBMC Public Health.20131337310.1186/1471-2458-13-373365368123601556Open DOISearch in Google Scholar
Manosuthi W, Ongwandee S, Bhakeecheep S, Leechawengwongs M, Ruxrungtham K, Phanuphak P, et al. Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand. AIDS Res Ther. 2015; 12:12. 10.1186/s12981-015-0053-z.ManosuthiWOngwandeeSBhakeecheepSLeechawengwongsMRuxrungthamKPhanuphakPGuidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, ThailandAIDS Res Ther.2015121210.1186/s12981-015-0053-z440733325908935Open DOISearch in Google Scholar
Sungkanuparph S, Sukasem C, Kiertiburanakul S, Pasomsub E, Chantratita W. Emergence of HIV-1 drug resistance mutations among antiretroviral-naive HIV-1-infected patients after rapid scaling up of antiretroviral therapy in Thailand. J Int AIDS Soc. 2012; 15:12. 10.1186/1758-2652-15-12.SungkanuparphSSukasemCKiertiburanakulSPasomsubEChantratitaW.Emergence of HIV-1 drug resistance mutations among antiretroviral-naive HIV-1-infected patients after rapid scaling up of antiretroviral therapy in ThailandJ Int AIDS Soc.2012151210.1186/1758-2652-15-12333468522410286Open DOISearch in Google Scholar
Kiertiburanakul S, Pinsai S, Chantratita W, Pasomsub E, Leechawengwongs M, Thipmontree W, et al. Prevalence of primary HIV drug resistance in Thailand detected by short reverse transcriptase genotypic resistance assay. PloS One. 2016; 11:e0147945. 10.1371/journal.pone.0147945.KiertiburanakulSPinsaiSChantratitaWPasomsubELeechawengwongsMThipmontreeWPrevalence of primary HIV drug resistance in Thailand detected by short reverse transcriptase genotypic resistance assayPloS One.201611e014794510.1371/journal.pone.0147945473477026828876Open DOISearch in Google Scholar
Boucoiran I, Tulloch K, Pick N, Kakkar F, van Schalkwyk J, Money D, et al. A case series of third-trimester raltegravir initiation: impact on maternal HIV-1 viral load and obstetrical outcomes. Can J Infect Dis Med Microbiol. 2015; 26:145-50.BoucoiranITullochKPickNKakkarFvan SchalkwykJMoneyDA case series of third-trimester raltegravir initiation: impact on maternal HIV-1 viral load and obstetrical outcomesCan J Infect Dis Med Microbiol.2015261455010.1155/2015/731043450784026236356Search in Google Scholar
De Hoffer L, Di Biagio A, Bruzzone B, Sticchi L, Prinapori R, Gerbaldo D, et al. Use of raltegravir in a late presenter HIV-1 woman in advanced gestational age: case report and literature review. J Chemother. 2013; 25:181-3.De HofferLDi BiagioABruzzoneBSticchiLPrinaporiRGerbaldoDUse of raltegravir in a late presenter HIV-1 woman in advanced gestational age: case report and literature reviewJ Chemother.201325181310.1179/1973947812Y.0000000066Search in Google Scholar
Thepnarong N, Puthanakit T, Chaithongwongwatthana S, Anugulruengkitt S, Anunsittichai O, Theerawit T, et al. Intensification of antiretroviral treatment with raltegravir for late-presenting HIV-infected pregnant women. 9th IAS Conference on HIV Science. July 23-26, 2017, Paris, France. Oral presentation abstract No. A-854-0187-01967.ThepnarongNPuthanakitTChaithongwongwatthanaSAnugulruengkittSAnunsittichaiOTheerawitTIntensification of antiretroviral treatment with raltegravir for late-presenting HIV-infected pregnant women9th IAS Conference on HIV ScienceJuly 23-262017Paris, FranceOral presentationabstract No. A-854-0187-01967Search in Google Scholar
Pinnetti C, Baroncelli S, Villani P, Fantoni M, Tozzi V, De Luca A, et al. Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy. J Antimicrob Chemother. 2010; 65:2050-2.PinnettiCBaroncelliSVillaniPFantoniMTozziVDe LucaARapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancyJ Antimicrob Chemother.2010652050210.1093/jac/dkq264Search in Google Scholar
Nobrega I, Travassos AG, Haguihara T, Amorim F, Brites C. Use of raltegravir in late-presenting HIV-infected pregnant women. AIDS Res Hum Retroviruses. 2013; 29:1451-4.NobregaITravassosAGHaguiharaTAmorimFBritesC.Use of raltegravir in late-presenting HIV-infected pregnant womenAIDS Res Hum Retroviruses.2013291451410.1089/aid.2013.0059Search in Google Scholar
Renet S, Closon A, Brochet MS, Bussieres JF, Boucher M. Increase in transaminase levels following the use of raltegravir in a woman with a high HIV viral load at 35 weeks of pregnancy. J Obstet Gynaecol Can. 2013; 35:68-72.RenetSClosonABrochetMSBussieresJFBoucherM.Increase in transaminase levels following the use of raltegravir in a woman with a high HIV viral load at 35 weeks of pregnancyJ Obstet Gynaecol Can.201335687210.1016/S1701-2163(15)31051-3Search in Google Scholar
Gomes S, Lopes C, Pinto E. Folate and folic acid in the periconceptional period: recommendations from official health organizations in thirty-six countries worldwide and WHO. Public Health Nutr. 2016; 19: 176-89.GomesSLopesCPintoE.Folate and folic acid in the periconceptional period: recommendations from official health organizations in thirty-six countries worldwide and WHOPublic Health Nutr.2016191768910.1017/S1368980015000555Search in Google Scholar
Rollins N, Mahy M, Becquet R, Kuhn L, Creek T, Mofenson L. Estimates of peripartum and postnatal mother-to-child transmission probabilities of HIV for use in Spectrum and other population-based models. Sex Transm Infect. 2012; 88 Suppl 2:i44-51.RollinsNMahyMBecquetRKuhnLCreekTMofensonL.Estimates of peripartum and postnatal mother-to-child transmission probabilities of HIV for use in Spectrum and other population-based modelsSex Transm Infect.2012882i445110.1136/sextrans-2012-050709Search in Google Scholar
Shaffer N, Chuachoowong R, Mock PA, Bhadrakom C, Siriwasin W, Young NL, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. Lancet. 1999; 353:773-80.ShafferNChuachoowongRMockPABhadrakomCSiriwasinWYoungNLShort-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study GroupLancet.19993537738010.1016/S0140-6736(98)10411-7Search in Google Scholar
Eshleman SH, Guay LA, Mwatha A, Brown E, Musoke P, Mmiro F, et al. Comparison of mother-to-child transmission rates in Ugandan women with subtype A versus D HIV-1 who received single-dose nevirapine prophylaxis: HIV Network For Prevention Trials 012. J Acquir Immune Defic Syndr. 2005; 39:593-7.EshlemanSHGuayLAMwathaABrownEMusokePMmiroFComparison of mother-to-child transmission rates in Ugandan women with subtype A versus D HIV-1 who received single-dose nevirapine prophylaxis: HIV Network For Prevention Trials 012J Acquir Immune Defic Syndr.2005395937Search in Google Scholar
Mirochnick M, Dorenbaum A, Blanchard S, Cunningham CK, Gelber RD, Mofenson L, et al. Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose. J Acquir Immune Defic Syndr. 2003; 33:153-6.MirochnickMDorenbaumABlanchardSCunninghamCKGelberRDMofensonLPredose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine doseJ Acquir Immune Defic Syndr.200333153610.1097/00126334-200306010-0000612794547Search in Google Scholar
World Health Organization. Programmatic update: use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. Executive Summary. Geneva: World Health Organization; 2012.World Health OrganizationProgrammatic update: use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infantsExecutive SummaryGenevaWorld Health Organization2012Search in Google Scholar
McIntyre JA, Hopley M, Moodley D, Eklund M, Gray GE, Hall DB, et al. Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial. PLoS Med. 2009; 6:e1000172. 10.1371/journal.pmed.1000172.McIntyreJAHopleyMMoodleyDEklundMGrayGEHallDBEfficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trialPLoS Med.20096e100017210.1371/journal.pmed.1000172276076119859531Open DOISearch in Google Scholar
Cressey TR, Green H, Khoo S, Treluyer JM, Compagnucci A, Saidi Y, et al. Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children. Clin Infect Dis. 2008; 46:1601-8.CresseyTRGreenHKhooSTreluyerJMCompagnucciASaidiYPlasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected childrenClin Infect Dis.2008461601810.1086/587657359713018419497Search in Google Scholar
Trancart S, Charreau I, Marchou B, Bocquentin M, Molina JM, Izopet J, et al. Presence of lamivudine or emtricitabine is associated with reduced emergence of nonnucleoside reverse transcriptase inhibitor mutations in an efavirenz-based intermittent antiretroviral treatment regimen. Antimicrob Agents Chemother. 2012; 56:1655-7.TrancartSCharreauIMarchouBBocquentinMMolinaJMIzopetJPresence of lamivudine or emtricitabine is associated with reduced emergence of nonnucleoside reverse transcriptase inhibitor mutations in an efavirenz-based intermittent antiretroviral treatment regimenAntimicrob Agents Chemother.2012561655710.1128/AAC.05452-11329488022203586Search in Google Scholar
Patel D, Cortina-Borja M, Thorne C, Newell ML. Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women. Clin Infect Dis. 2007; 44:1647-56.PatelDCortina-BorjaMThorneCNewellML.Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant womenClin Infect Dis.20074416475610.1086/51828417516411Search in Google Scholar
Townsend CL, Byrne L, Cortina-Borja M, Thorne C, de Ruiter A, Lyall H, et al. Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000–2011. Aids. 2014; 28:1049-57.TownsendCLByrneLCortina-BorjaMThorneCde RuiterALyallHEarlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000–2011Aids.20142810495710.1097/QAD.000000000000021224566097Search in Google Scholar
Mandelbrot L, Tubiana R, Le Chenadec J, Dollfus C, Faye A, Pannier E, et al. No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception. Clin Infect Dis. 2015; 61: 1715-25.MandelbrotLTubianaRLe ChenadecJDollfusCFayeAPannierENo perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conceptionClin Infect Dis.20156117152510.1093/cid/civ57826197844Search in Google Scholar
Bitnun A, Samson L, Chun TW, Kakkar F, Brophy J, Murray D, et al. Early initiation of combination antiretroviral therapy in HIV-1-infected newborns can achieve sustained virologic suppression with low frequency of CD4+ T cells carrying HIV in peripheral blood. Clin Infect Dis. 2014; 59:1012-9.BitnunASamsonLChunTWKakkarFBrophyJMurrayDEarly initiation of combination antiretroviral therapy in HIV-1-infected newborns can achieve sustained virologic suppression with low frequency of CD4+ T cells carrying HIV in peripheral bloodClin Infect Dis.2014591012910.1093/cid/ciu432418438324917662Search in Google Scholar
Anugulruengkitt S, Suntarattiwong P, Ounchanum P, Srirompotong U, Jantarabenjakul W, Sophonphan J, et al. Safety of 6-week triple antiretroviral prophylaxis in high risk HIV-exposed infants. Conference on Retroviruses and Opportunistic Infections. CROI 2017, Seattle, USA. February 13–16, 2017. Poster presentation. Abstract Number: 759. Available at http://www.croiconference.org/sessions/safety-6-week-triple-antiretroviral-prophylaxis-high-risk-hiv-exposed-infants. Accessed March 17, 2017.AnugulruengkittSSuntarattiwongPOunchanumPSrirompotongUJantarabenjakulWSophonphanJSafety of 6-week triple antiretroviral prophylaxis in high risk HIV-exposed infantsConference on Retroviruses and Opportunistic Infections. CROI 2017, Seattle, USAFebruary 13–162017Poster presentation. Abstract Number: 759. Available athttp://www.croiconference.org/sessions/safety-6-week-triple-antiretroviral-prophylaxis-high-risk-hiv-exposed-infantsAccessed March 172017Search in Google Scholar
Hitti J, Andersen J, McComsey G, Liu T, Melvin A, Smith L, et al. Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084. Am J Obstet Gynecol. 2007; 196:331.e1-7.HittiJAndersenJMcComseyGLiuTMelvinASmithLProtease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084Am J Obstet Gynecol.2007196331e1710.1016/j.ajog.2006.11.03717403409Search in Google Scholar
Senise JF, Castelo A, Martinez M. Current treatment strategies, complications and considerations for the use of HIV antiretroviral therapy during pregnancy. AIDS Rev. 2011; 13:198-213.SeniseJFCasteloAMartinezM.Current treatment strategies, complications and considerations for the use of HIV antiretroviral therapy during pregnancyAIDS Rev.201113198213Search in Google Scholar
Ahmad H, Mehta NJ, Manikal VM, Lamoste TJ, Chapnick EK, Lutwick LI, et al. Pneumocystis carinii pneumonia in pregnancy. Chest. 2001; 120:666-71.AhmadHMehtaNJManikalVMLamosteTJChapnickEKLutwickLIPneumocystis carinii pneumonia in pregnancyChest.20011206667110.1378/chest.120.2.66611502676Search in Google Scholar
Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Accessed July 23, 2015.Panel on Opportunistic Infections in HIV-Infected Adults and AdolescentsGuidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of AmericaAvailable athttp://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdfAccessed July 23, 2015Search in Google Scholar
Pilmis B, Jullien V, Sobel J, Lecuit M, Lortholary O, Charlier C. Antifungal drugs during pregnancy: an updated review. J Antimicrob Chemother. 2015; 70: 14-22.PilmisBJullienVSobelJLecuitMLortholaryOCharlierC.Antifungal drugs during pregnancy: an updated reviewJ Antimicrob Chemother.201570142210.1093/jac/dku35525204341Search in Google Scholar
AIDS info. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. [online] 2016. Available at https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-oi-prevention-and-treatment-guidelines/333/cryptococcosis. Accessed April 11, 2017.AIDS infoGuidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents[online] 2016. Available athttps://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-oi-prevention-and-treatment-guidelines/333/cryptococcosisAccessed April 11, 2017Search in Google Scholar
International Perinatal HIVG. Duration of ruptured membranes and vertical transmission of HIV-1: a meta-analysis from 15 prospective cohort studies. Aids. 2001; 15:357-68.International PerinatalHIVG.Duration of ruptured membranes and vertical transmission of HIV-1: a meta-analysis from 15 prospective cohort studiesAids.2001153576810.1097/00002030-200102160-0000911273216Search in Google Scholar
Peters H, Byrne L, De Ruiter A, Francis K, Harding K, Taylor GP, et al. Duration of ruptured membranes and mother-to-child HIV transmission: a prospective population-based surveillance study. BJOG. 2016; 123: 975-81.PetersHByrneLDe RuiterAFrancisKHardingKTaylorGPDuration of ruptured membranes and mother-to-child HIV transmission: a prospective population-based surveillance studyBJOG20161239758110.1111/1471-0528.1344226011825Search in Google Scholar
Cotter AM, Brookfield KF, Duthely LM, Gonzalez Quintero VH, Potter JE, O’Sullivan MJ. Duration of membrane rupture and risk of perinatal transmission of HIV-1 in the era of combination antiretroviral therapy. Am J Obstet Gynecol. 2012; 207:482.e1-5. 10.1016/j.ajog.2012.10.862CotterAMBrookfieldKFDuthelyLMGonzalez QuinteroVHPotterJEO’SullivanMJ.Duration of membrane rupture and risk of perinatal transmission of HIV-1 in the era of combination antiretroviral therapyAm J Obstet Gynecol.2012207482e1-510.1016/j.ajog.2012.10.86223103331Open DOISearch in Google Scholar
Read JS, Newell MK. Efficacy and safety of cesarean delivery for prevention of mother-to-child transmission of HIV-1. The Cochrane database of systematic reviews. 2005; CD005479.ReadJSNewellMK.Efficacy and safety of cesarean delivery for prevention of mother-to-child transmission of HIV-1The Cochrane database of systematic reviews.2005CD00547910.1002/14651858.CD00547916235405Search in Google Scholar
Reshi P, Lone IM. Human immunodeficiency virus and pregnancy. Arch Gynecol Obstet. 2010; 281: 781-92.ReshiPLoneIM.Human immunodeficiency virus and pregnancyArch Gynecol Obstet.20102817819210.1007/s00404-009-1334-320035338Search in Google Scholar
Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf. Accessed June 18, 2015.Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal TransmissionRecommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United StatesAvailable athttp://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdfAccessedJune 182015Search in Google Scholar
Rodger A, Bruun T, Cambiano V, Vernazza P, Estrada V, Lunzen J, et al. HIV transmission risk through condomless sex if HIV+ partner on suppressive ART: PARTNER study. 21st Conference on Retroviruses and Opportunistic Infections CROI 2014. Boston, Massachusetts. March 3–6, 2014. Abstract 153LB. Available at http://www.croiconference.org/sessions/hiv-transmission-risk-through-condomless-sex-if-hiv-partner-suppressive-art-partner-study. Accessed Jan 25, 2017.RodgerABruunTCambianoVVernazzaPEstradaVLunzenJHIV transmission risk through condomless sex if HIV+ partner on suppressive ART: PARTNER study21st Conference on Retroviruses and Opportunistic Infections CROI 2014BostonMassachusettsMarch 3–62014Abstract 153LB. Available athttp://www.croiconference.org/sessions/hiv-transmission-risk-through-condomless-sex-if-hiv-partner-suppressive-art-partner-studyAccessed Jan 25, 2017Search in Google Scholar
Richey LE, Halperin J. Acute human immunodeficiency virus infection. Am J Med Sci. 2013; 345:136-42.RicheyLEHalperinJ.Acute human immunodeficiency virus infectionAm J Med Sci.20133451364210.1097/MAJ.0b013e31825d4b8823095473Search in Google Scholar
Centers for Disease Control and Prevention. Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults. MMWR. 2012; 61:586-9.Centers for Disease Control and PreventionInterim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adultsMMWR.2012615869Search in Google Scholar
Lampe MA, Smith DK, Anderson GJ, Edwards AE, Nesheim SR. Achieving safe conception in HIV-discordant couples: the potential role of oral preexposure prophylaxis (PrEP) in the United States. Am J Obstet Gynecol. 2011; 204:488.e1-8. doi:10.1016/ j.ajog.2011.02.026.LampeMASmithDKAndersonGJEdwardsAENesheimSR.Achieving safe conception in HIV-discordant couples: the potential role of oral preexposure prophylaxis (PrEP) in the United StatesAm J Obstet Gynecol.2011204488e1-810.1016/j.ajog.2011.02.02621457911Open DOISearch in Google Scholar
De Schacht C, Mabunda N, Ferreira OC, Ismael N, Calu N, Santos I, et al. High HIV incidence in the postpartum period sustains vertical transmission in settings with generalized epidemics: a cohort study in Southern Mozambique. J Int AIDS Soc. 2014; 17: 18808. 10.7448/IAS.17.1.18808.De SchachtCMabundaNFerreiraOCIsmaelNCaluNSantosIHigh HIV incidence in the postpartum period sustains vertical transmission in settings with generalized epidemics: a cohort study in Southern MozambiqueJ Int AIDS Soc.2014171880810.7448/IAS.17.1.18808394650524629842Open DOISearch in Google Scholar
Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002; 29:484-94.CooperERCharuratMMofensonLHansonICPittJDiazCCombination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmissionJ Acquir Immune Defic Syndr.2002294849410.1097/00042560-200204150-00009Search in Google Scholar
World Health Organization. Medical eligibility criteria for contraceptive use, 4th ed. Geneva: WHO Press; 2010.World Health OrganizationMedical eligibility criteria for contraceptive use4thGenevaWHO Press2010Search in Google Scholar
Heikinheimo O, Lehtovirta P, Aho I, Ristola M, Paavonen J. The levonorgestrel-releasing intrauterine system in human immunodeficiency virus-infected women: a 5-year follow-up study. Am J Obstet Gynecol. 2011; 204:126.e1-4. 10.1016/j.ajog.2010.09.002.HeikinheimoOLehtovirtaPAhoIRistolaMPaavonenJ.The levonorgestrel-releasing intrauterine system in human immunodeficiency virus-infected women: a 5-year follow-up studyAm J Obstet Gynecol.2011204126e1-410.1016/j.ajog.2010.09.00221035781Open DOISearch in Google Scholar
World Health Organization. Medical eligibility criteria for contraceptive use. 5th ed. 2015. Available at http://apps.who.int/iris/bitstream/10665/181468/1/9789241549158_eng.pdf?ua=1. Accessed January 11, 2017.World Health OrganizationMedical eligibility criteria for contraceptive use5th2015Available athttp://apps.who.int/iris/bitstream/10665/181468/1/9789241549158_eng.pdf?ua=1Accessed January 11, 2017Search in Google Scholar
Leticee N, Viard JP, Yamgnane A, Karmochkine M, Benachi A. Contraceptive failure of etonogestrel implant in patients treated with antiretrovirals including efavirenz. Contraception. 2012; 85:425-7.LeticeeNViardJPYamgnaneAKarmochkineMBenachiA.Contraceptive failure of etonogestrel implant in patients treated with antiretrovirals including efavirenzContraception.201285425710.1016/j.contraception.2011.09.00522036046Search in Google Scholar
Watts DH, Park JG, Cohn SE, Yu S, Hitti J, Stek A, et al. Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093. Contraception. 2008; 77:84-90.WattsDHParkJGCohnSEYuSHittiJStekASafety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093Contraception.200877849010.1016/j.contraception.2007.10.002242431318226670Search in Google Scholar
Tseng A, Hills-Nieminen C. Drug interactions between antiretrovirals and hormonal contraceptives. Expert Opin Drug Metab Toxicol. 2013; 9:559-72.TsengAHills-NieminenC.Drug interactions between antiretrovirals and hormonal contraceptivesExpert Opin Drug Metab Toxicol.201395597210.1517/17425255.2013.772579Search in Google Scholar
Chokephaibulkit K, Chuachoowong R, Chotpitayasunondh T, Chearskul S, Vanprapar N, Waranawat N, et al. Evaluating a new strategy for prophylaxis to prevent Pneumocystis cariniipneumonia in HIV-exposed infants in Thailand. Bangkok Collaborative Perinatal HIV Transmission Study Group. Aids. 2000; 14:1563-9.ChokephaibulkitKChuachoowongRChotpitayasunondhTChearskulSVanpraparNWaranawatNEvaluating a new strategy for prophylaxis to prevent Pneumocystis cariniipneumonia in HIV-exposed infants in Thailand. Bangkok Collaborative Perinatal HIV Transmission Study GroupAids.2000141563910.1097/00002030-200007280-00012Search in Google Scholar
Rojanawiwat A, Samleerat T, Thaisri H, Lolekha R, Puthanakit T, Kosalaraksa P. Implementation of dried blood spot HIV DNA PCR testing at birth among infants born to HIV-infected mothers in Thailand. 8th International Workshop on HIV Pediatrics. July 15–16, 2016. Durban, South Africa. Poster presentation abstract No. P60.RojanawiwatASamleeratTThaisriHLolekhaRPuthanakitTKosalaraksaP.Implementation of dried blood spot HIV DNA PCR testing at birth among infants born to HIV-infected mothers in Thailand8th International Workshop on HIV PediatricsJuly 15–162016Durban, South AfricaPoster presentation abstract No. P60Search in Google Scholar
Lolekha R, Pavaputanondh P, Puthanakit T, Kosalaraksa P, Petdachai W, Borkird T. Implementation of an active case management network to identify HIV-infected infants and accelerate the initiation of antiretroviral therapy, Thailand 2015. 21st International AIDS conference. July 2016. Durban, South Africa. Poster presentation abstract No. TUPEE483.LolekhaRPavaputanondhPPuthanakitTKosalaraksaPPetdachaiWBorkirdT.Implementation of an active case management network to identify HIV-infected infants and accelerate the initiation of antiretroviral therapy, Thailand 201521st International AIDS conferenceJuly 2016Durban, South AfricaPoster presentationabstract NoTUPEE483Search in Google Scholar
Shiau S, Strehlau R, Technau KG, Patel F, Arpadi SM, Coovadia A, et al. Early age at start of antiretroviral therapy associated with better virologic control after initial suppression in HIV-infected infants. Aids. 2017; 31:355-64.ShiauSStrehlauRTechnauKGPatelFArpadiSMCoovadiaAEarly age at start of antiretroviral therapy associated with better virologic control after initial suppression in HIV-infected infantsAids.2017313556410.1097/QAD.0000000000001312Search in Google Scholar
Klein N, Palma P, Luzuriaga K, Pahwa S, Nastouli E, Gibb DM, et al. Early antiretroviral therapy in children perinatally infected with HIV: a unique opportunity to implement immunotherapeutic approaches to prolong viral remission. Lancet Infect Dis. 2015; 15: 1108-14.KleinNPalmaPLuzuriagaKPahwaSNastouliEGibbDMEarly antiretroviral therapy in children perinatally infected with HIV: a unique opportunity to implement immunotherapeutic approaches to prolong viral remissionLancet Infect Dis.20151511081410.1016/S1473-3099(15)00052-3Search in Google Scholar
Ananworanich J, Robb ML. The transient HIV remission in the Mississippi baby: why is this good news? J Int AIDS Soc. 2014; 17:19859. 10.7448/IAS.17.1.19859.AnanworanichJRobbML.The transient HIV remission in the Mississippi baby: why is this good news?J Int AIDS Soc.2014171985910.7448/IAS.17.1.19859424085225416415Open DOISearch in Google Scholar
Persaud D, Gay H, Ziemniak C, Chen YH, Piatak M, Jr., Chun TW, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med. 2013; 369:1828-35.PersaudDGayHZiemniakCChenYHPiatakM Jr.ChunTWAbsence of detectable HIV-1 viremia after treatment cessation in an infantN Engl J Med.201336918283510.1056/NEJMoa1302976395475424152233Search in Google Scholar
Massanella M, Ananworanich J, Leyre L, Jupimai T, Sawangsinth P, de Souza M. Impact of T-cell homeostasis and thymic output on the seeding of the HIV reservoir in infants. 9th IAS Conference on HIV Science. July 23–26, 2017. Paris, France. Poster abstract No. A-854-0114-03024.MassanellaMAnanworanichJLeyreLJupimaiTSawangsinthPde SouzaM.Impact of T-cell homeostasis and thymic output on the seeding of the HIV reservoir in infants9th IAS Conference on HIV ScienceJuly 23–262017Paris, FrancePosterabstract No. A-854-0114-03024Search in Google Scholar
Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008; 359:2233-44.ViolariACottonMFGibbDMBabikerAGSteynJMadhiSAEarly antiretroviral therapy and mortality among HIV-infected infantsN Engl J Med.200835922334410.1056/NEJMoa0800971295002119020325Search in Google Scholar
Capparelli EV, Mirochnick M, Dankner WM, Blanchard S, Mofenson L, McSherry GD, et al. Pharmacokinetics and tolerance of zidovudine in preterm infants. J Pediatr. 2003; 142:47-52.CapparelliEVMirochnickMDanknerWMBlanchardSMofensonLMcSherryGDPharmacokinetics and tolerance of zidovudine in preterm infantsJ Pediatr.2003142475210.1067/mpd.2003.mpd033512520254Search in Google Scholar
